Since multi-target drug combination strategies have shown great promise in improving treatment efficacy and overcoming drug resistance, we assessed the combination of gp130 inhibition by BZA with standard-of-care chemotherapy drugs in well-characterised patient-derived colorectal cancer organoids (Fig. 5B). This evidence concerns the gene IL6ST and colorectal cancer.